MedTrace Logo

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

NCT05116878 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-09-08

No results posted yet for this study

Summary

The purpose of this research is to develop a therapeutic agent to help improve facial nerve outcomes and ultimately improve long-term quality-of-life following surgical resection of vestibular schwannomas. It is possible the therapeutic agent may impact tumor control rates as well, and this will also be studied. Using rigorous scientific methods, we will assess whether these factors are impacted by the treatment agent (Omega-3) versus placebo control (cellulose).

Conditions

  • Vestibular Schwannoma

Interventions

DIETARY_SUPPLEMENT

Omega-3

One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative

DIETARY_SUPPLEMENT

Placebo

One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative

Sponsors & Collaborators

Principal Investigators

  • Michael Link, MD · Mayo Clinic

  • Lucas P Carlstrom, MD, PhD · Mayo Clinic

  • Matthew L Carlson, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-08-02
Completion
2023-08-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116878 on ClinicalTrials.gov